Join to View Full Profile
22 S Greene StHematology Oncology, S9d10Baltimore, MD 21201
Phone+1 410-328-7157
Fax+1 410-328-6896
Dr. Weinstock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2005 - 2008
Albert Einstein College of MedicineClass of 2005
Certifications & Licensure
MD State Medical License 2011 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Publications & Presentations
PubMed
- 2 citationsFDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.Jaleh Fallah, Brian L Heiss, Hee-Koung Joeng, Chana Weinstock, Xin Gao
Clinical Cancer Research. 2024-11-15 - 3 citationsFDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.Michael H Brave, William F Maguire, Chana Weinstock, Hui Zhang, Xin Gao
Clinical Cancer Research. 2024-11-01 - A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura Fernandes
Clinical Cancer Research. 2024-08-01
Lectures
- An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death lig...2019 ASCO Annual Meeting - 6/1/2019
- Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) ant...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Checkpoint Inhibitors in Heavily Pretreated Bladder Ca: Long-Term DataAugust 23rd, 2019
Urothelial Carcinoma Drug Shortages: Insights From ASCO GUFebruary 6th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
